Detection of liver metastases from pancreatic cancer using FDG PET

Journal of Nuclear Medicine

Volumn 40, Issue 2, 1999, Pages 250-255

  Fröhlich, Andrea ^a   Diederichs, Christoph G ^a   Staib, Ludger ^a   Vogel, Jochen ^a   Beger, Hans G ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

FDG PET; Liver metastases; Pancreatic cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; LIVER SCINTISCANNING; MALE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0343692401     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Amikura K, Kobari M, Matsumo S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreat. 1995;17:139-146.
2. Gilbert HA, Kagan AR, Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L, ed. Fundamental Aspects of Metastasis. Amsterdam, The Netherlands: North-Holland; 1976:385-405.
3. Kemeni N, Sugarbaker PH. Treatment of metastatic cancer to liver. In: DeVita VC, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. 3rd ed. Philadelphia, PA: JB Lippincott; 1989:2275-2298.
4. Clark JW, Glicksman AS, Wanebo HJ. Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer. 1996;78(suppl):688-693.
5. Goldie JH. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 1987;14:1-7
6. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307-1317.
7. Baker ME, Pelley R. Hepatic metastases; basic principles and implications for radiologists. Radiology. 1995;197:329-337.
8. Bluemke DA, Cameron JL, Hruban RH, et al. Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology. 1995;197:381-385.
9. Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma, Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993;25:58-68.
10. Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: Value of dual-phase helical CT in assessing resectability. Radiology. 1998;206:373-378.
11. Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning for pancreatic cancer. Am J Surg. 1986;151:76-80.
12. Bennett WF, Bova JG. Review of hepatic imaging and a problem-oriented approach to liver masses. Hepatology. 1990;12:761-775.
13. Wernecke K, Rummeny E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. AJR. 1991;157:731-739.
14. Zerhouni EA, Rutter C, Hamilton SR, et al. CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology. 1996;200:443-451.
15. Rummeny EJ, Reimer P, Daldrup H, Peters PE, Detektion von Lebertumoren. Radiologe. 1995;35:252-258.
16. Meijer S, Paul MA, Cuesta MA, Blomjous J. Intra-operative ultrasound in detection of liver metastases. Eur J Cancer. 1995;31A:1210-1211.
17. Soyer P, Levesque M, Elias D, Zeitoun G, Roche A. Detection of liver metastases from colorectal cancer: comparison of intraoperative US and CT during arterial portography. Radiology. 1992;183:541-544.
18. Small WC, Mehard WB, Langmo LS, et al. Preoperative determination of the resectability of hepatic tumors: efficacy of CT during arterial portography. AJR. 1993;161:319-322.
19. Peterson MS, Baron RL, Dodd GD III, et al. Hepatic parenchymal perfusion defects detected with CTAP: imaging-pathologic correlation. Radiology. 1992;185: 149-155.
20. Soyer P, Lacheheb D, Levesque M. False-positive CT portography: correlation with pathologic findings. AJR. 1993;160:285-289.
21. Urban BA, Fishman EK, Kuhlman JE, Kawashima A, Hennessey JG, Siegelman SS. Detection of focal hepatic lesions with spiral CT: comparison of 4- and 8-mm interscan spacing. AJR. 1993;160:783-785.
22. Warburg O. The Metabolism of Tumors. New York, NY: Richard R. Smith, Inc.: 1931:129-169.
23. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Büll U. Ergebnisse der Positronenemisionstomographie mit Fluor-18-markierter Fluordesoxyglukose bei Differentialdiagnose und Staging des Pankreaskarzinoms. Radiologe. 1996;36:435-440.
24. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995;36: 771-777.
25. 18F-fluorodeoxyglucose and positron emission tomography in pancreatic adenocarcinoma. Dig Surg. 1994;11:360-365.
26. 18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133-1137.
27. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21-26.
28. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703-707.
29. 18F]FDG positron emission tomography. J Comput Assist Tomogr. 1990;14:370-374.
30. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;4:700-708.
31. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333-339.
32. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1987;27:235-238.
33. Schmidlin P. Iterative Verfahren für die Emissionstomographie. Nuklearmedizin. 1990;3:155-158.
34. Hustinx R, Paulus P, Benoit T, Jerusalem G, Jacquet N, Rigo P. Clinical value of whole-body FDG-PET in the detection of liver metastases: preliminary results [abstract]. Eur J Nucl Med. 1996;23:1110.
35. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
36. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med. 1996;37:371-374.
37. 18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr. 1989;13:829-831.
38. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.